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Paola Francica1 and Sven Rottenberg1,2*Editorial summary
Inhibitors of poly(ADP-ribose) polymerase (PARPi) have
entered the clinic for the treatment of patients with
cancers that lack homology-directed DNA repair, but
drug resistance remains a clinical hurdle. Recent
advances in the identification of PARPi resistance
mechanisms have yielded a better understanding of
DNA end protection and the relevance of endogenous
poly(ADP-ribose) glycohydrolase, highlighting new
vulnerabilities.structures. The unligated fragments may requireHow do PARP inhibitors work?
In 2005, two landmark studies demonstrated the striking
sensitivity of BRCA1- and BRCA2-deficient tumor cells
to poly(ADP-ribose) polymerase (PARP) inhibition, and
since then several PARP inhibitors (PARPi) have been
developed for clinical use (reviewed in [1]). As a prime
example of the concept of synthetic lethality in cancer,
PARPi have scored successes in the treatment of patients
with BRCA1/2-mutated cancers [1]. BRCA1 and BRCA2
are key players in the error-free repair of DNA
double-strand breaks (DSBs) by homologous recombin-
ation (HR). When cells become HR-deficient because of
the loss of BRCA1 or BRCA2, DSBs need to be repaired
by alternative error-prone repair pathways, resulting in
chromosome deletions, translocations, and subsequent
cell death. This vulnerability is exploited by treating
HR-deficient tumors with PARPi.
The molecular mechanisms that underlie the selective
killing of HR-deficient cells by PARPi are not yet com-
pletely clear. Initially, it was thought that PARPi cause
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toxic DSBs in BRCA1/2-defective cells. This model was
challenged by the discovery that PARP can be trapped
on DNA at the sites of unrepaired SSBs (reviewed in [1])
and that this causes the lethal effect of PARPi. Yet the
exact nature of the DNA structures on which PARP en-
zymes are trapped remains undefined. Recently, Hanzli-
kova et al. [2] suggested that unligated Okazaki
fragments (short DNA sequences that are synthesized
discontinuously to create the lagging strand during DNA
replication) resulting from PARPi are the responsible
HR-mediated repair for their removal, either directly as
single-strand gaps or following their conversion into
DSBs by nucleases or DNA replication fork collapse.
Hanzlikova et al. [2] concluded that PARP1 also acts as
a sensor of unligated Okazaki fragments during DNA
replication, facilitating their repair. In addition, Massimo
Lopes and colleagues suggested that PARPi treatment
promotes premature, RECQ1-dependent restart of re-
versed replication forks. This results in unrestrained
replication fork progression and in the subsequent accu-
mulation of DSBs (reviewed in [1]).
Surprisingly, PARPi may also prevent tumorigenesis
by impeding the interactions of PARP1 with the cyclic
GMP–AMP synthase (cGAS) [3]. The cytosolic DNA
sensor cGAS has recently been shown to link gen-
omic instability to the innate immune response. DNA
damage-induced nuclear translocation of cGAS in-
hibits HR by interacting directly with PARP1 and
thereby suppressing the PARP1-timeless complex [3].
It is unlikely though that the effect of PARPi on
cGAS compensates for the tumorigenic potential of
PARP1 trapped on chromatin.
Learning from mechanisms of PARPi resistance
As with all targeted therapies that have entered the
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drug resistance (reviewed in [1]). Understanding the
underlying mechanisms may not only be useful for at-
tempts to counteract PARPi resistance; this knowledge
has also yielded novel insights into basic mechanisms of
the DNA damage response. Among the resistance mecha-
nisms identified to date, (partial) restoration of homology-
directed DNA repair is frequently observed in various
model systems and in patients, highlighting the HR defect
as the Achilles heel for PARPi (reviewed in [1]).
An obvious mechanism of HR restoration is the reactiva-
tion of BRCA1/2 function as a result of secondary genetic
alterations (reviewed in [1]). More intriguing are mecha-
nisms of BRCA1-independent partial HR restoration: first,
this type of HR restoration was shown to occur owing to
inactivation of the p53-binding protein 1 (53BP1) (reviewed
in [1]). 53BP1 plays a crucial role in maintaining the
balance between HR and non-homologous end joining
(NHEJ), which is shifted toward NHEJ in BRCA1-deficient
cells. Mechanistically, 53BP1 promotes NHEJ by inhibiting
the extensive nucleolytic resection of DNA termini required
for HR repair. Hence, loss of 53BP1 function facilitates
BRCA1-independent end resection and conveys PARPi re-
sistance. Follow-up studies identified that the inactivation
of downstream factors of 53BP1-mediated repair, such as
RIF1 and REV7, also results in the restoration of DNA end
resection and thereby promotes homology-mediated repair
(reviewed in [1]). However, the ultimate effectors of the
53BP1 pathway responsible for DNA end protection remain
unknown.
Recently, several groups have identified the molecular
mechanisms by which 53BP1 mediates its function in
DNA repair (reviewed in [1]). Using ascorbate peroxidase-
based proximity labeling or functional genetic screens for
PARPi resistance factors in BRCA1-deficient cells, a new
53BP1 effector complex called shieldin was discovered.
This complex comprises C20orf196 (also known as
SHLD1), FAM35A (SHLD2), CTC-534A2.2 (SHLD3) and
REV7. Shieldin functions as a downstream effector in the
53BP1 pathway by restraining DNA end resection. Mech-
anistically, the shieldin complex localizes directly to DSB
sites and its loss impairs NHEJ, leads to defective im-
munoglobulin class switching, and causes hyper-resection.
Mutations in genes that encode the shieldin subunits
cause PARPi resistance in BRCA1-deficient cells but not
in BRCA2-deficient cells. Ghezraoui et al. [4] found
that shieldin is involved in distinct DSB repair activ-
ities of the 53BP1 pathway: it is essential for DNA
end protection and NHEJ during class-switch recom-
bination, but it is dispensable for REV7-dependent in-
terstrand cross-link repair.
Another factor that regulates 53BP1-dependent NHEJ
is DYNLL1 [5]. Binding of DYNLL1 to 53BP1 stimulates
its recruitment to DSB sites, and stabilizes its interactionwith DNA damage-associated chromatin. Moreover, He
et al. [6] found that DYNLL1 also binds to MRE11 to
limit DNA end resection in BRCA1-deficient cells. Given
its role in the degradation of reversed replication forks,
it would be interesting to investigate whether MRE11 in-
hibition by DYNLL1 binding also protects replication
forks, similar to the loss of PTIP (reviewed in [1]).
Moreover, we and others found that PARPi resistance in
BRCA1-deficient cells is caused by the loss of the CTC1–
STN1–TEN1 (CST) complex, suggesting that CST–Polα-
mediated fill-in helps to control the repair of DSBs by the
53BP1-RIF1-REV7-Shieldin pathway [7, 8]. Although it re-
mains to be established whether CST-mediated inhibition
of end resection at non-telomeric DSBs is dependent on
Polα, the CST complex might contribute to preventing
resection at DSBs in addition to its role in telomere
maintenance.
In contrast to these mechanisms of partial HR restor-
ation in BRCA1-deficient cells, HR-independent resist-
ance to PARPi has been enigmatic. However, Gogola
et al. [9] recently made an interesting observation. They
combined genetic screens with multi-omics analysis of
matched PARPi-sensitive and -resistant Brca2-mutated
mouse mammary tumors and observed that loss of PAR
glycohydrolase (PARG), the main enzyme responsible for
degrading nuclear PAR, was involved in a major resist-
ance mechanism [9]. Our data show that endogenous
PARG activity is crucial for the success of PARPi therapy
and that PARG suppression restores PARP1 signaling
upon PARPi treatment. Hence, PARG activity may be
another useful predictive marker for PARPi therapy.
Intriguingly, HR restoration was not observed in
BRCA2-deficient tumor cells that acquired PARPi resist-
ance ([9] and unpublished). These data raise the ques-
tion of whether BRCA1 is less essential than BRCA2 for
homology-directed DNA repair. To date, our data show
that loss of the 53BP1-RIF1-REV7-Shieldin-CST path-
way only partially restores BRCA1 deficiency. It remains
to be shown whether loss of members of this pathway
can be fully compensated for in mice with a complete
Brca1 depletion.
Implications for translation into the clinic
Despite the plethora of PARPi resistance mechanisms,
there is also hope: the analysis of PARPi resistance mecha-
nisms revealed new vulnerabilities that can be exploited
therapeutically. For instance, we and others have shown
that loss of the 53BP1-RIF1-REV7-Shieldin-CST pathway
in PARPi-resistant BRCA1-deficient cells results in hyper-
sensitivity to ionizing radiation [10, 11]. This is most prob-
ably due to the role of this pathway in NHEJ: in contrast
to PARPi, DSB induction by ionizing radiation is less
dependent on the S phase of the cell cycle and therefore
relies more on repair through the NHEJ pathway than on
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PARPi-resistant tumors that lost PARG [9]. This may be
caused by the depletion of the pool of non-PARylated
PARP1 necessary to catalyze DNA repair. Radiotherapy
or a treatment with radiomimetic drugs might therefore
serve as a useful treatment option for PARPi-resistant
tumors in which no genetic reversion of BRCA1/2 is
detected. It also raises the question of whether alternat-
ing treatment cycles of PARPi and radiomimetic drugs
would be more successful than the PARPi maintenance
treatment currently used in platinum-sensitive ovarian
cancer.
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